Top Markets
#1 Trillions Trillions +4,371.27%
#2 Ozapay Ozapay +38.46%
#3 UnifAI Network UnifAI Network +23.35%
#4 Aria.AI Aria.AI +22.13%
#5 Zano Zano +17.76%
#6 Osaka Protocol Osaka Protocol +14.37%
#7 StakeStone StakeStone +14.34%
#8 Vestra DAO Vestra DAO +12.12%
#9 River Pts River Pts +10.84%
#10 Janction Janction +10.23%
Coin of the day
Trillions Trillions
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Peringkat dalam Saham #99999
Acticor Biotech SAS operates as a clinical stage biotechnology company that... Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.
Harga Saham
$0.28545656
Kapitalisasi Pasar
$4.50M
Perubahan (1 hari)
5.97%
Perubahan (1 tahun)
0.00%
Negara
FR
Perdagangan Acticor Biotech SAS (ALACT)

Kategori

Healthcare
Pendapatan untuk Acticor Biotech SAS (ALACT)
Pendapatan pada Jun 2024 TTM: 0.00
Menurut laporan keuangan terbaru dari Acticor Biotech SAS, pendapatan saat ini (TTM) adalah 0.00. Pada tahun 2022, perusahaan menghasilkan pendapatan sebesar 0.00 sama dengan pendapatan pada tahun 2021 yang sebesar 0.00. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Acticor Biotech SAS dari 2010 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $57.46K -99.46%
2017 $10.59M -27.26%
2016 $14.56M -21.24%
2015 $18.49M -22.69%
2014 $23.92M -0.83%
2013 $24.11M 21.74%
2012 $19.81M 44.80%
2011 $13.68M 52.66%
2010 $8.96M 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU